Nithin 6wxd

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 10: Line 10:
== Introduction ==
== Introduction ==
-
The SARS-CoV-2 main protease (Mpro) performs 11 essential cleavages in the viral polyprotein. many SARS-CoV-2 proteins have close relatives in other viruses from the SARS family. One such protein is non-structural protein 9 (Nsp9). This protein is believed to help the virus replicate, increase its virulence, and support the production of viral genomic RNA. Because of this, understanding Nsp9 is important for studying how the virus grows.
 
-
Because humans do not have similar proteases, Mpro is a highly selective antiviral target.They obtained the structure in two forms:
 
-
Apo form – without anything bound
+
The SARS-CoV-2 Non-structural protein 9 (Nsp9) is a small but essential RNA-binding protein encoded by
 +
SARS-CoV-2. It contributes to viral replication by stabilizing viral RNA and assisting the
 +
replication–transcription machinery. Nsp9 is highly conserved across coronaviruses, indicating
 +
that its structure is crucial for efficient genome replication.
-
A peptide-bound form, which happened unexpectedly. The bound peptide (sequence: LEVL) actually comes from a rhinovirus 3C protease.
+
crystal structure in two states:
-
The structure showed that SARS-CoV-2 Nsp9 is highly conserved across the Nsp9 family, meaning the protein keeps a similar shape in different coronaviruses. The peptide-binding site was found near the dimer interface, and its binding caused small changes in the way the two Nsp9 monomers sit next to each other.
+
* **Apo Nsp9** – Nsp9 without any ligand
 +
* **Peptide-bound Nsp9** – unexpectedly containing a short peptide (**LEVL**) derived from a
 +
rhinovirus 3C protease cleavage tag used during purification
-
Overall, the study successfully established a protocol to produce Nsp9, determined its 3D structure, and discovered a previously unknown peptide-binding site. This site may be important for better understanding the function of Nsp9 and its role in viral replication.
+
The peptide was found bound close to the **dimer interface**, causing subtle but significant
 +
changes in the relative orientation of the two Nsp9 monomers. Since Nsp9 functions as a
 +
homodimer during RNA binding, even small shifts in this interface may influence replication
 +
efficiency and protein–RNA interactions.
-
The 6XWD structure, solved during early COVID-19 outbreak, revealed how a covalent inhibitor locks
+
The structure confirmed that SARS-CoV-2 Nsp9 maintains a highly conserved **oblong β-barrel
-
the enzyme in an inactive state.
+
fold**, similar to Nsp9 structures from SARS-CoV and other coronaviruses. The discovery of an
 +
unexpected peptide-binding site suggests that Nsp9 may interact with regulatory elements or
 +
protein partners during viral replication.
</structureSection>
</structureSection>
== Structure ==
== Structure ==
-
Mpro functions as a homodimer, and each protomer is organized into three domains.
+
The SARS-CoV-2 Nsp9 monomer adopts a compact **7-stranded β-barrel fold**, a hallmark feature
 +
of the Nsp9 family. Two monomers form a **homodimer**, which is necessary for RNA-binding
 +
function.
-
<scene name='10/1096916/Domain_i/1'>Domain I</scene> (residues 8–101) consists of a β-barrel-like scaffold that forms part of thecatalytic cleft and positions His41 of the catalytic dyad.The central domain of Nsp9 is composed of seven β-strands that fold into an oblong β-barrel structure 1
 
-
This β-barrel acts as the main stabilizing framework of the protein and is responsible for maintaining the shape and rigidity necessary for function. Because this fold is nearly identical across SARS-CoV and SARS-CoV-2, it suggests that the structural design is crucial for maintaining viral replication efficiency 2
 
-
Domain I is built mainly from antiparallel β-strands arranged into a β-barrel–like fold.
 
-
This domain forms one half of the active site cleft, and it holds His41, which is part of the catalytic dyad.
 
-
Structurally, Domain I acts like a rigid frame that shapes the substrate-binding groove.
 
-
Functionally, it stabilizes the substrate as it enters the active site and helps maintain the enzyme’s catalytic geometry.
 
-
Because of its β-barrel framework, Domain I gives both stability and specificity to the protease.
 
-
<scene name='10/1096916/Domain_ii/1'>Domain II (residues 102–184)</scene> continues the β-barrel architecture and contains Cys145, forming the second half of the His41–Cys145 catalytic dyad. Together,
 
-
Domains I and II generate the deep substrate-binding
 
-
groove that includes the S1, S2, and S4 pockets essential for recognizing viral polyprotein
 
-
cleavage sequences. Domain II continues the β-barrel architecture seen in Domain I.
 
-
Together with Domain I, it forms the deep substrate-binding trench where viral polyproteins bind.
 
-
Most importantly, Domain II houses Cys145, the second residue of the catalytic dyad (His41–Cys145).
 
-
This domain constructs the major substrate-recognition pockets:
 
-
S1 pocket → Recognizes Gln at P1
+
=== β-Barrel Core ===
 +
The Nsp9 monomer contains **seven antiparallel β-strands** arranged into a barrel-like fold.
 +
This β-barrel provides rigidity and forms the structural foundation needed for RNA interaction.
 +
The fold is nearly identical to SARS-CoV Nsp9, highlighting strong evolutionary conservation.
-
S2 pocket → Prefers hydrophobic residues
+
=== Dimer Interface ===
 +
Nsp9 functions as a **homodimer**. The dimer interface is primarily stabilized by:
 +
* β5–β6 region interactions
 +
* Hydrophobic packing
 +
* A conserved **GxGxG motif** situated near the dimerization surface
-
S4 pocket → Flexible, accommodates bulky groups
+
The alignment of the two monomers creates a positively charged groove thought to accommodate
 +
viral RNA.
-
In structures like 6XWD, this domain makes key hydrogen bonds with inhibitors.
+
=== Peptide-Binding Site (LEVL peptide) ===
-
Overall, Domain II is the functional center of catalysis — it executes cleavage.
+
In the peptide-bound structure (6WXD), a short peptide (**LEVL**) occupies a groove near the
 +
dimer interface. This interaction was **not biologically intended** but arose from purification
 +
artifacts involving the rhinovirus 3C protease.
-
<scene name='10/1096916/Domain_iii/1'>Domain III (residues 201–303)</scene>is composed of α-helices and is primarily responsible for dimerization.
+
Nevertheless, the peptide influences monomer orientation, providing insight into how small
-
Domain III consists of five α-helices packed tightly together.
+
ligands or interacting partners may modulate Nsp9 dimer architecture.
-
This domain does not participate directly in catalysis but is essential for dimerization, which is required for enzyme activity.
+
-
A long connecting loop between Domain II and Domain III acts like a hinge that helps the enzyme shift between active and inactive states.
+
-
Domain III forms stabilizing interactions with the opposite protomer, and without this domain, Mpro remains mostly inactive.
+
-
Thus, Domain III functions as the activation switch of the protease by enabling dimer formation and structural locking.Its interactions with the opposite protomer stabilize the active conformation of the enzyme. Because Mpro activity depends on dimerization, Domain III indirectly controls catalytic function. Overall, the coordinated architecture of these three domains enables Mpro to recognize, bind, and cleave viral substrates with high specificity.
+
 +
Key features:
 +
* Peptide binds in a shallow hydrophobic groove
 +
* Contacts β-barrel residues at the interface
 +
* Causes measurable shifts in dimer alignment
 +
* Suggests the site may be relevant for RNA or protein interactions
-
 
+
== Conserved Motif ==
-
== Catalytic Site ==
+
A highly conserved **Gly-rich GxGxG loop** is found near the dimerization surface.
-
The catalytic activity of the SARS-CoV-2 Main Protease (Mpro) is driven by a conserved **His41–Cys145 catalytic dyad**. This dyad carries out peptide bond hydrolysis and is essential for all cleavage reactions during viral polyprotein processing.
+
Evolutionary conservation suggests this motif stabilizes the fold and may contribute to RNA
-
 
+
association. Mutations in this region in related coronaviruses reduce replication efficiency.
-
* '''<scene name='10/1096916/His41/1'>His41</scene>''' functions as a general base. It extracts a proton from Cys145, converting it into a highly reactive thiolate.
+
-
* '''Cys145''' acts as the nucleophile. Once activated, it attacks the carbonyl carbon of the substrate’s scissile peptide bond.
+
-
 
+
-
Structurally, this catalytic dyad is positioned at the interface between **Domain I** and **Domain II**, forming a deep, well-defined cleft. This location creates an optimal environment for catalysis and aligns the substrate in the correct orientation for cleavage.
+
-
 
+
-
Surrounding the dyad is the **oxyanion hole**, formed primarily by backbone atoms of **Gly143** and **Ser144**. This region stabilizes the negatively charged tetrahedral intermediate that appears during the reaction. The substrate-recognition pockets — **S1, S2, and S4** — are also formed by residues from Domains I and II, ensuring that Mpro selectively cleaves sequences containing a Gln residue at the P1 position.
+
-
 
+
-
Together, the catalytic dyad, oxyanion hole, and surrounding pockets form a tightly coordinated active-site architecture that ensures high specificity and efficiency in viral polyprotein processing.
+
-
 
+
-
 
+
-
The 6XWD structure captures Mpro bound to a covalent peptide-like inhibitor, revealing how the active site accommodates small-molecule or peptide-based antiviral compounds. The inhibitor occupies the **S1**, **S2**, and **S4** substrate-binding pockets that are formed at the interface of Domain I and Domain II.
+
-
 
+
-
In the **S1 pocket**, the inhibitor forms stabilizing **hydrogen bonds** with key residues such as **His163** and **Glu166**, which normally recognize the P1 glutamine residue in the natural viral polyprotein. These interactions anchor the inhibitor deeply within the catalytic groove and contribute strongly to specificity.
+
-
 
+
-
The **S2 pocket** is predominantly hydrophobic, shaped by residues including **Met49** and **His41**, allowing the inhibitor’s hydrophobic moieties to pack tightly into this region. This hydrophobic enclosure helps stabilize the inhibitor and mimics how the viral substrate engages the protease during cleavage.
+
-
 
+
-
A defining feature of the 6XWD structure is the formation of a **covalent thioether bond** between the inhibitor’s reactive “warhead” group and the catalytic **Cys145**. This covalent linkage locks the enzyme into an inhibited state, preventing further catalytic turnover. The covalent attachment demonstrates how irreversible inhibitors can be designed to block Mpro function with high potency.
+
-
 
+
-
Together, these interactions illustrate the principles of Mpro inhibitor design: accurate pocket fitting, hydrogen-bond anchoring in S1, hydrophobic complementarity in S2, and covalent engagement of Cys145.
+
-
 
+
-
 
+
-
 
+
-
 
+
-
== Covalent Inhibition ==
+
-
In the 6XWD structure, the inhibitor achieves irreversible inhibition by forming a **covalent thioether bond** with the catalytic residue **Cys145**. This covalent attachment occurs after the inhibitor’s electrophilic “warhead” reacts with the nucleophilic thiolate form of Cys145, which is activated by His41. Once this bond forms, the catalytic cysteine is no longer available to attack incoming peptide substrates.
+
-
 
+
-
This covalent linkage effectively **blocks the active site**, preventing substrate entry and locking Mpro in a non-functional state. Unlike reversible inhibitors that can dissociate, covalent inhibitors permanently inactivate the enzyme until new protein molecules are synthesized by the virus. This is a powerful strategy because Mpro activity is essential for viral replication, and shutting it down disrupts the processing of all viral polyprotein cleavage sites.
+
-
 
+
-
Structural analysis of the covalent bond reveals that the inhibitor remains tightly positioned within the **S1–S2–S4 pockets**, and the surrounding residues—including Gly143 and Ser144 of the oxyanion hole—help stabilize the bound state. The fixed orientation of the inhibitor further ensures that the catalytic machinery cannot proceed through the proteolytic cycle.
+
-
 
+
-
Overall, covalent inhibition represents a promising antiviral design approach because it combines high selectivity, strong binding, and long-lasting catalytic shutdown.
+
-
 
+
== Biological Significance ==
== Biological Significance ==
-
Mpro is one of the most critical enzymes for SARS-CoV-2 replication because it performs
+
Nsp9 is essential for:
-
multiple cleavage steps required to generate the proteins needed for viral RNA synthesis [3].
+
* Assembly of the replication–transcription complex
-
Since humans do not have a close structural or functional homolog of Mpro, it provides an
+
* Stabilization of viral RNA
-
excellent therapeutic window and has become one of the most successful antiviral targets [3].
+
* Viral protein–protein interactions
 +
* Efficient SARS-CoV-2 genome replication
-
The 6XWD structure played an important role in the early COVID-19 drug-development efforts.
+
The structural analysis in this paper showed:
-
By revealing how a covalent inhibitor fits into the S1, S2, and S4 pockets and forms a
+
* Nsp9’s β-barrel is rigid and conserved
-
stable thioether bond with Cys145, this structure directly guided the design of clinical
+
* Dimerization is critical for function
-
Mpro inhibitors such as nirmatrelvir (the active component of Paxlovid) [4]. The structural
+
* The unexpected LEVL peptide reveals a **potential regulatory pocket**
-
features seen in 6XWD—like pocket geometry, hydrogen-bond patterns, and warhead positioning—
+
* Small ligands may modulate Nsp9 dimer dynamics
-
continue to support ongoing efforts to design improved inhibitors with better potency,
+
-
broader variant coverage, and reduced chances of resistance [4].
+
-
These structural insights also enable follow-up experiments such as testing inhibitor
+
Because Nsp9 lacks close human homologs, identifying druggable sites on this protein could
-
sensitivity in newly emerging Mpro variants, performing kinetic assays to assess
+
offer future antiviral opportunities.
-
resistance-linked mutations, and designing new scaffolds using fragment-based approaches [5].
+
Line 120: Line 93:
-
[2] Protein Data Bank: PDB 6XWD
+
[2] Protein Data Bank: PDB 6WXD
-
 
+
-
 
+
-
[3] Role of Mpro in viral polyprotein processing and replication
+
-
An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19. Science, 2021. DOI: https://doi.org/10.1126/science.abl4784
+
-
 
+
-
 
+
-
[4] Structure-guided design of covalent Mpro inhibitors (6XWD; nirmatrelvir development) Covalent small-molecule inhibitors of SARS-CoV-2 Mpro. Journal — review article. PubMed link: https://pubmed.ncbi.nlm.nih.gov/39121741/
+
-
 
+
-
 
+
-
[5] Ongoing studies on variant sensitivity and fragment-based inhibitor discovery
+
-
.Preclinical evaluation of the SARS-CoV-2 Mpro inhibitor RAY1216. Nature Microbiology, 2024. PMCID: PMC10994847
+
-
. Recent Advances in SARS-CoV-2 Main Protease Inhibitors. Review 2023 — summarizing structural and inhibitor design progress.
+
-
Author
 
-
Racha Nithin
+
[
-
Indian Institute of science education and research pune
+
-
course :Bi3323 Aug 2025
+

Revision as of 16:14, 30 November 2025

SARS-CoV-2 Main Protease (Mpro) – Structure and Covalent Inhibition

This page provides structural overview of the SARS-CoV-2 main protease (Mpro), based on the iScience 2020 study (DOI: https://doi.org/10.1016/j.isci.2020.101258) and the crystal structure 6XWD. In this study , the researchers produced SARS-CoV-2 Nsp9 in the lab and sloved its X-ray crystal structure

PDB ID 6xwd

Drag the structure with the mouse to rotate

Contents

Structure

The SARS-CoV-2 Nsp9 monomer adopts a compact **7-stranded β-barrel fold**, a hallmark feature of the Nsp9 family. Two monomers form a **homodimer**, which is necessary for RNA-binding function.


β-Barrel Core

The Nsp9 monomer contains **seven antiparallel β-strands** arranged into a barrel-like fold. This β-barrel provides rigidity and forms the structural foundation needed for RNA interaction. The fold is nearly identical to SARS-CoV Nsp9, highlighting strong evolutionary conservation.

Dimer Interface

Nsp9 functions as a **homodimer**. The dimer interface is primarily stabilized by:

  • β5–β6 region interactions
  • Hydrophobic packing
  • A conserved **GxGxG motif** situated near the dimerization surface

The alignment of the two monomers creates a positively charged groove thought to accommodate viral RNA.

Peptide-Binding Site (LEVL peptide)

In the peptide-bound structure (6WXD), a short peptide (**LEVL**) occupies a groove near the dimer interface. This interaction was **not biologically intended** but arose from purification artifacts involving the rhinovirus 3C protease.

Nevertheless, the peptide influences monomer orientation, providing insight into how small ligands or interacting partners may modulate Nsp9 dimer architecture.

Key features:

  • Peptide binds in a shallow hydrophobic groove
  • Contacts β-barrel residues at the interface
  • Causes measurable shifts in dimer alignment
  • Suggests the site may be relevant for RNA or protein interactions

Conserved Motif

A highly conserved **Gly-rich GxGxG loop** is found near the dimerization surface. Evolutionary conservation suggests this motif stabilizes the fold and may contribute to RNA association. Mutations in this region in related coronaviruses reduce replication efficiency.

Biological Significance

Nsp9 is essential for:

  • Assembly of the replication–transcription complex
  • Stabilization of viral RNA
  • Viral protein–protein interactions
  • Efficient SARS-CoV-2 genome replication

The structural analysis in this paper showed:

  • Nsp9’s β-barrel is rigid and conserved
  • Dimerization is critical for function
  • The unexpected LEVL peptide reveals a **potential regulatory pocket**
  • Small ligands may modulate Nsp9 dimer dynamics

Because Nsp9 lacks close human homologs, identifying druggable sites on this protein could offer future antiviral opportunities.


References

[1] iScience (2020). Structural Basis of SARS-CoV-2 Main Protease Inhibition. https://doi.org/10.1016/j.isci.2020.101258


[2] Protein Data Bank: PDB 6WXD


[

Proteopedia Page Contributors and Editors (what is this?)

Racha Nithin

Retrieved from "http://52.214.119.220/wiki/index.php/Nithin_6wxd"
Personal tools